New pill aims to slow ALS progression
Disease control
Not yet recruiting
This study tests a new oral drug called Kamlanoflast in 40 people with ALS. The goal is to see if it is safe, tolerable, and can reduce inflammation and slow decline in muscle function over 24 weeks. Participants must be 18-75 years old, diagnosed with ALS, and have had symptoms …
Phase: PHASE1, PHASE2 • Sponsor: Inflammasome Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC